Toggle Main Menu Toggle Search

Open Access padlockePrints

Landscape of TET2 Mutations: From Hematological Malignancies to Solid Tumors

Lookup NU author(s): Zoe Hawking, Professor James AllanORCiD

Downloads


Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).


Abstract

© 2025 The Author(s). Cancer Medicine published by John Wiley & Sons Ltd. Background: The ten–eleven translocation (TET) enzyme family is a key regulator of DNA methylation, responsible for the conversion of 5-methylcytosine to 5-hydroxymethylcytosine to promote locus-specific demethylation. Thus, it is not surprising that loss or attenuation of TET enzymes is implicated in genomic hypermethylation and transcriptional reprogramming that drives cancer development. Somatic mutations in TET2 are observed in the bone marrow of 5%–10% of healthy adults over 65 years of age, imparting a hematopoietic stem cell advantage and subsequent clonal hematopoiesis of indeterminate potential (CHIP), a condition which is associated with increased risk of myeloid malignancy. Somatic TET2 mutations are frequently reported in myeloid disorders, including myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). Evidence suggests that TET2 mutations also affect prognosis in myeloid leukemia and other hematopoietic malignancies. However, there is a paucity of collated data on the frequency of TET2 mutations in solid human cancers. Objectives: We review the published literature on TET2 mutation in human solid cancers and explore their frequency and impact on patient outcomes. Results & Conclusions: Somatic TET2 mutations are reported in numerous solid human cancers, including those arising in the skin, lung and prostate. Many of the somatic TET2 mutations reported in solid cancers are recurrent, suggesting functionality. There is also evidence to suggest that somatic TET2 mutations affect prognosis in solid human cancers.


Publication metadata

Author(s): Hawking ZL, Allan JM

Publication type: Review

Publication status: Published

Journal: Cancer Medicine

Year: 2025

Volume: 14

Issue: 6

Online publication date: 21/03/2025

Acceptance date: 09/03/2025

ISSN (print): 2045-7634

ISSN (electronic): 2045-7634

Publisher: John Wiley and Sons Inc

URL: https://doi.org/10.1002/cam4.70792

DOI: 10.1002/cam4.70792

Data Access Statement: The authors have nothing to report.


Share